$RPRX

Royalty Pharma (RPRX) agreed to pay Neurimmune up to $425 million for a 3% to 4% royalty on AstraZeneca (AZN) candidate cliramitug, including $125 million upfront and $125 million in 2027 plus $175 million tied to clinical and regulatory milestones. Cliramitug is in Phase 3 DepleTTR-CM with readouts expected in 2028. RPRX Q1 2026 Portfolio Receipts rose 10% to $925 million; AZN H1 2026 revenue rose 6% and core profit/EPS rose 11%.

Royalty Pharma (RPRX) reported Q2 net income attributable to the company fell to $18 million from $32 million a year earlier. Adjusted EBITDA rose to $736 million from $633 million. Royalty Receipts grew 14% to $768 million, and Portfolio Receipts rose 6% to $773 million. The company raised 2026 Portfolio Receipts guidance to $3.400 billion to $3.500 billion.

Royalty Pharma plc (RPRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rprx-20260630rpplcpressxre.htm EX-99.1 Document Press Release August 5, 2026 R oyalty Pharma reports second quarter 2026 results Portfolio Rece ipts growth o f 6% to $773 million ; Royalty Receipts growth of 14% Net cash provided by operating activities of $728 million

Royalty Pharma plc said it will appoint Greg Raskin, M.D. as Senior Vice President, Head of Academic Initiatives, effective August 2026. He will lead outreach to academic and non-profit institutions and oversee the Royalty Pharma Translational Prize. The company noted he previously worked at Memorial Sloan Kettering and AllianceBernstein.

Biotech weekly roundup highlights EU approval for AstraZeneca’s Etcamah plus CDK4/6 inhibitors in ESR1-mutant ER+/HER2- advanced breast cancer, and accelerated FDA approval for GSK’s Jideytro in ROS1+ NSCLC. J&J received FDA De Novo for OTTAVA and reported Phase 3 PFS/OS gains for Talvey combos. Other items include deals (RGEN-BioLife, RPRX royalty buy) and trial updates for LLY, CLDX, and others.

Royalty Pharma will pay Neurimmune $125 million upfront for a 3% to 4% royalty on worldwide net sales of cliramitug. Neurimmune will receive another $125 million in Q1 2027 and up to $175 million tied to clinical and regulatory milestones. Cliramitug is in Phase III DepleTTR-CM, with results expected in 2028.

Royalty Pharma plc (RPRX) said it will acquire Neurimmune’s royalty interest in AstraZeneca’s (AZN) cliramitug for up to $425 million, according to the company. The deal covers a portion of the existing royalty interest tied to the drug.

Royalty Pharma will buy part of Neurimmune’s royalty interest in AstraZeneca’s Phase 3 cliramitug, in a deal worth up to $425 million. Royalty Pharma pays $125 million upfront, with $125 million in Q1 2027 plus up to $175 million tied to milestones. It receives 3% to 4% royalties on worldwide net sales. AstraZeneca expects Phase 3 results in 2028.

Royalty Pharma said it acquired a royalty interest from Neurimmune tied to AstraZeneca’s cliramitug, a Phase 3 ATTR-CM drug. The deal totals up to $425M, including $125M upfront. Results are expected in 2028, and AstraZeneca projects peak sales of $3-5B, expanding Royalty Pharma’s royalty portfolio.

Royalty Pharma (RPRX) said it will buy Neurimmune’s royalty interest in AstraZeneca’s cliramitug for up to $425 million, including $125 million upfront. The deal grants RPRX a 3% to 4% royalty on worldwide net sales, with additional payments tied to milestones. Cliramitug is in Phase 3, with results expected in 2028.